In this video from Thursday's Market Checkup, Motley Fool health-care analysts David Williamson and Max Macaluso dive into the biggest stories impacting health-care investors on the market today.
In this segment, a look at some big winners during the past two days in the biotech space. Pernix (NYSEMKT: PTX) saw a nearly 70% pop upward yesterday as the company settled a few housekeeping items, including hiring a new CEO, settling a pending legal matter, and securing $65 million in funding, a lifesaver compared to its cash-on-hand situation prior to this. Myriad Genetics (NASDAQ:MYGN), maker of a test for breast cancer, is up 15% after its fiscal second-quarter net income soared by 43.7%, to $50.4 million, with sales increasing $55 million, to $204.1 million. Repros Therapeutics (NASDAQ: RPRX) is up 15% after positive meetings with the FDA over Androxal, its testosterone replacement drug. The company now believes it will not have to run any additional safety studies, and will be able to file for approval this year, which had investors cheering. And OraSure (NASDAQ:OSUR) is up 10% after reporting strong earnings, with revenue coming in at $28.8 million, which was a 30% improvement and a solid beat.